Research Triangle Park, NC — Protocol deviations are not patient-centric, writes VP of Client Services Jim Wahl in a new article published by Applied Clinical Trials magazine.

During TruLab’s webinar “Patient Burden in Clinical Trials: Ethics of Biospecimen Management,” Jim sat down with a patient who unfortunately walked away from his participation in a clinical trial feeling “not taken care of” and “dehumanized” by the process.

One of the main culprits? Protocol deviations that led to significant additional burden.

“Sponsors can no longer afford to not do their utmost to minimize protocol deviations that harm the patient-centricity of their studies,” Jim writes.

Read the full article at Applied Clinical Trials Online.

About TruLab

Founded in 2018, TruLab is now the leading provider of technology for clinical trial oversight, dedicated to enhancing data quality, and mitigating risks in drug development. TruLab currently supports four top pharmaceutical companies as well as numerous biotechnology companies to speed patient screening and enrollment, ensure data integrity, and prevent protocol deviations.